Literature DB >> 2425124

[Significance of clinical and laboratory chemical parameters for the course and prognosis of non-Hodgkin's lymphomas].

B Steinke, J Mau.   

Abstract

Using a regression model, the prognostic significance of clinical and biochemical parameters as well as of histology was analyzed in a group of 336 patients with Non-Hodgkin's lymphoma. A stochastic process model was used for evaluation of the course of disease. With respect to overall survival, serum-LDH-activity, performance status, and the histologically defined grade of malignancy were found to be the most important prognostic parameters, as well as age, though that to a lesser extent. In the course of disease, stage was the most relevant factor for achievement of a complete remission. In patients without remission, survival was determined mainly by histology and serum-LDH-activity; the latter was also of importance for duration of remission. Our study shows that histology is not the only prognostic factor in NHL but that other parameters, mainly serum-LDH-activity and performance status, also have to be considered in comparing different groups of patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425124     DOI: 10.1007/bf01713170

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  25 in total

1.  Multivariate analysis of prognostic factors in the non-Hodgkin's malignant lymphomas.

Authors:  C D Bloomfield; A Goldman; F Dick; R D Brunning; B J Kennedy
Journal:  Cancer       Date:  1974-03       Impact factor: 6.860

2.  Treatment of advanced diffuse histiocytic lymphoma: an analysis of prognostic variables.

Authors:  B Koziner; C Little; S Passe; H T Thaler; R Sklaroff; D J Straus; B J Lee; B D Clarkson
Journal:  Cancer       Date:  1982-04-15       Impact factor: 6.860

Review 3.  Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group.

Authors:  G Brittinger; H Bartels; H Common; E Dühmke; H H Fülle; U Gunzer; T Gyenes; R Heinz; E König; P Meusers
Journal:  Hematol Oncol       Date:  1984 Jul-Sep       Impact factor: 5.271

4.  Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.

Authors:  R I Fisher; V T DeVita; S M Hubbard; D L Longo; R Wesley; B A Chabner; R C Young
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

5.  Prognostic factors in Burkitt's lymphoma: importance of total tumor burden.

Authors:  I Magrath; Y J Lee; T Anderson; W Henle; J Ziegler; R Simon; P Schein
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

6.  Morphological classification of non-Hodgkin malignant lymphoma. II. Comparison between Rappaport's classification and the Kiel classification.

Authors:  B Glimelius; H Hagberg; C Sundström
Journal:  Scand J Haematol       Date:  1983-01

7.  CHOP-firstline treatment in NHL with unfavorable prognosis--evaluation of therapeutic response and factors influencing prognosis.

Authors:  R Heinz; E Neumann; P Aiginger; J Pont; J Schüller; G Walcher; H Hanak; T Radaszkiewicz; E Sinn; M Wirth
Journal:  Blut       Date:  1985-05

8.  Prognostic significance of serum lactate dehydrogenase in malignant lymphoma.

Authors:  R J Schneider; K Seibert; S Passe; C Little; T Gee; B J Lee; V Miké; C W Young
Journal:  Cancer       Date:  1980-07-01       Impact factor: 6.860

9.  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma.

Authors:  R I Fisher; S M Hubbard; V T DeVita; C W Berard; R Wesley; J Cossman; R C Young
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

10.  Malignant lymphoma. II Prognostic factors and response to treatment of 473 patients at the National Cancer Institute.

Authors:  T Anderson; V T DeVita; R M Simon; C W Berard; G P Canellos; A J Garvin; R C Young
Journal:  Cancer       Date:  1982-12-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.